CrushSCI.com
138.6Average days
131.5Median days
26Fastest days
282Longest days
1412025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

26 days

CAR immunotherapy for cancer: from ex vivo manufacturing to in vivo immune cell engineering

Authors
Ziqiang Liu; Dezheng Kong; Pengwu Liang; Zhengze Li; Tingting Tan; Xin Dong; Ruizhen Li; Lifeng Li; Yi Zhang; Guozhu XieShow moreShow less
Affiliations
1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China; 2. Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China; 3. Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; 4. The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 5. National Engineering Laboratory for Internet Medical Systems and Applications, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China; 6. Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
282 days

RBP1-driven retinol metabolism in tumor-associated lymphatic endothelial cells orchestrates triple-negative breast cancer progression and lymphatic metastasis

Authors
Nieves Montenegro-Navarro; Estefanía Díaz del Cerro; Carmen Jordán-Pérez; Enrique de Álava; Melissa García-CaballeroShow moreShow less
Affiliations
1. Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga, Málaga, Spain; 2. Biomedical Research Institute of Málaga and Nanotechnology Platform (IBIMA Plataforma BIONAND), Málaga, Spain; 3. Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Molecular Pathology of Sarcomas, Seville, Spain; 4. Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, SpainShow moreShow less
Source PDF DOI Publisher page
83 days

Distinct asciminib sensitivity profiles between BCR::ABL1 p190 and p210 isoforms

Authors
Elias Lagonik; Luke J. Quinlan; Elyse C. Page; Daniel P. McDougal; Laura N. Eadie; John B. Bruning; David T. Yeung; Timothy P. Hughes; Deborah L. WhiteShow moreShow less
Affiliations
1. Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia; 2. Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, Australia; 3. Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia; 4. Centre for Targeted Protein Degradation, University of Dundee, Dundee, Scotland; 5. Institute for Photonics and Advanced Sensing, School of Biological Sciences, The University of Adelaide, Adelaide, Australia; 6. Haematology Department, Royal Adelaide Hospital, Adelaide, Australia; 7. Australasian Leukaemia Lymphoma Group, Richmond, Australia; 8. Australian and New Zealand Children’s Haematology-Oncology Group, Clayton, AustraliaShow moreShow less
Source PDF DOI Publisher page
105 days

A non-IMiD multi-target degrader reactivates fetal hemoglobin

Authors
Jun Liu; Ziyang Shen; Shin-Young Park; Yanhua Dong; Na Yu; Jing Zeng; Hannah Lee; Braden Pate; Sophia Adamia; Kim Vanuytsel; Junyan Zhang; Shang-Chuen Wu; Adelaide Herman; Shiva Moein; Wenhui Li; Miao Liu; Chong Gao; Xi Tian; Zhaoji Liu; Junsu Kwon; Kunhua Qin; Christoph Budjan; Claire Shao; Jiajia Li; Ernie Lee; Sanjana Arji; Bee-hui Liu; Sean Stowell; John P. Manis; David Justus; Gerd A. Blobel; Hongbo R. Luo; Roger Belizaire; Yi Zheng; Sahand Hormoz; Mahmoud A. Bassal; Sarah Nikiforow; Jose A. Cancelas; Daniel E. Bauer; Daniel G. Tenen; Li ChaiShow moreShow less
Affiliations
1. Department of Pathology, Brigham and Women’s Hospital, Boston, USA; 2. Department of Pathology, Harvard Medical School, Boston, USA; 3. Division of Hematology/Oncology, Boston Children’s Hospital, Boston, USA; 4. Center for Regenerative Medicine (CReM), Boston University and Boston Medical Center, Boston, USA; 5. Beth Israel Deaconess Medical Center, Boston, USA; 6. Institute of Medical and Public Health Research, Ilia State University, Tbilisi, Georgia; 7. Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, USA; 8. Department of Systems Biology, Harvard Medical School, Boston, USA; 9. Department of Data Science, Dana-Farber Cancer Institute, Boston, USA; 10. Cancer Science Institute of Singapore, Singapore, Singapore; 11. Department of Laboratory Medicine, Boston Children’s Hospital, Boston, USA; 12. Department of Pathology, Dana-Farber Cancer Institute, Boston, USA; 13. Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 14. Harvard Stem Cell Institute, Harvard Medical School, Boston, USA; 15. Depts. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USAShow moreShow less
Source PDF DOI Publisher page
166 days

Subtype-resolved tumor-intrinsic programs in immune-cold breast cancer: mechanistic interactions, evidence gaps, and translational priorities

Authors
Hung-Yu Lin; Shin-Mae Wang; Pei-Yi ChuShow moreShow less
Affiliations
1. Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan; 2. Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan; 3. Department of Surgery, Show Chwan Memorial Hospital, Changhua, Taiwan; 4. Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan; 5. National Institute of Cancer Research, National Health Research Institutes, Tainan, TaiwanShow moreShow less
Source PDF DOI Publisher page
224 days

Comparative characterization of OncoPro™ and Wnt-based media reveals distinct phenotypic and pharmacologic states in patient-derived tumor organoids

Authors
Sofie Seghers; Maxim Le Compte; Felicia Rodrigues Fortes; Jana Baroen; Jasper Ott; Geert Roeyen; Vera Hartman; Samir Kumar-Singh; Lenny Coppens; Michiel de Maat; Niels Komen; Sylvie Van Den Broeck; Jody Valk; Wiebren Tjalma; Jeroen M. H. Hendriks; Paul Van Schil; Gilles Van Haesendonck; Sofia L. J. Peeters; Hans Prenen; Christophe DebenShow moreShow less
Affiliations
1. Center for Oncological Research (CORE), , University of Antwerp, Wilrijk, Belgium; 2. Department of Medical Oncology, University Hospital Antwerp (UZA), Edegem, Belgium; 3. Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT), University of Antwerp, Wilrijk, Belgium; 4. Environmental Intelligence Unit, Flemish Institute for Technological Research (VITO), Mol, Belgium; 5. Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp (UZA), Edegem, Belgium; 6. Molecular Pathology Group, Laboratory of Cell Biology & Histology, University of Antwerp, Wilrijk, Belgium; 7. Translational Neurosciences, University of Antwerp, Wilrijk, Belgium; 8. Department of Abdominal, Pediatric and Reconstructive Surgery, Antwerp University Hospital, Edegem, Belgium; 9. Antwerp ReSURG, Anatomy and Research Centre (ASTARC), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; 10. Multidisciplinary Breast Clinic—Unit Gynecological Oncology, University Hospital Antwerp (UZA), Edegem, Belgium; 11. Faculty of Medicine, University of Antwerp, Wilrijk, Belgium; 12. Department of Thoracic and Vascular, Surgery University Hospital Antwerp (UZA), Edegem, Belgium; 13. Department of Otorhinolaryngology, University Hospital Antwerp (UZA), Edegem, BelgiumShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Experimental Hematology & Oncology take to review a manuscript?

As of 2026-11-18, CrushSCI has 30 complete review records for Experimental Hematology & Oncology. The fastest paper went from submission to acceptance in 26 days (CAR immunotherapy for cancer: from ex vivo manufacturing to in vivo immune cell engineering, received 2026-10-01, accepted 2026-10-27); the slowest took 282 days. The average is 138.6 days and the median is 131.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.